Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe

 
• By Alaric DeArment
  
BeiGene took back full rights for its PD-1 inhibitor, Tevimbra • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer